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INTRODUCTION 
The purpose of renal replacement therapy for End Stage Renal 
Disease patients was to prolong and maintain quality of life. Despite the 
many attempts  to  do  renal  replacement  in  early  part  of  20th century, the 
first  successful  renal  transplant  was  done  in  1954  by  Murray  among  
identical twins.  
Introduction of calcineurin inhibitor in later part of twentieth 
century revolutionized the history of renal transplantation by reducing the 
short term morbidity and mortality. However the patients receiving 
calcineurin inhibitor were under the risk of calcineurin inhibitor 
nephrotoxicity in long run. The chronic nephrotoxic effects of calcineurin 
inhibitors associated with the renal parenchymal damage plays a major 
role in the pathogenesis of chronic renal dysfunction. Calcineurin 
inhibitor toxicity clinically characterized by tremor, hypertension, 
hypertrichosis and gum hypertrophy, biochemically by raising creatinine 
(graft dysfunction), hyperglycemia, hyperkalemia and hyperuricemia and 
histopathologicaly by isometric vacuolization, arterial nodular hyalinosis, 
striped fibrosis and interstitial atrophy.  
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The effect of toxicity was reversible in short term, became 
irreversible  in  long  term.   Lower  dose  results  in  graft  dysfunction  and  
rejection, higher dose results in toxicity  because of  its narrow 
therapeutic index ( little difference between toxic and therapeutic doses). 
So it was mandatory to adjust its dosage according   to measurements of 
the actual blood levels through therapeutic drug monitoring (TDM). The 
serum level of drug does not correlat with the degree of  nephrotoxicity in 
most of the occasion because of its varied pharmacokinetics, narrow 
therapeutic index, individual sensitivity to toxic effects.  .  
 Though there are few international studies on prevalence of 
calcineurin inhibitor toxicity and its clinico pathological correlation, a 
good study in this part of world is lacking . So, this study, attempt to find 
out the correlation among clinical, biochemical, drug trough level and 
histopathological features of calcineurin inhibitor toxicity. 
 
 
 
 
 
Aim of the 
Study 
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AIM OF THE STUDY 
 
To study the clinical, biochemical, whole blood trough level and 
histopathological correlation of calcineurin inhibitors (CNI) toxicity in 
renal allograft recipients 
 
  
Review of 
Literature 
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CALCINEURIN INHIBITORS 
Perhaps the most effective immunosuppressant drug, which served 
as the back bone of kidney transplant for past 2-3 decades. These 
comprise of  Cyclosporine and Tacrolimus, although they are structurally 
distinct and combined with distinct immunophilin, cyclophilin and FK 
Binding Protein which act through common path way by inhibiting 
dephosphatase  enzyme Calcineurin.  
Calcineurin catalyzed dephosphorylation was required for entry of 
cytoplasmic component of nuclear factor of activated T cells into nucleus 
where it combined with its nuclear counter part and induces number of 
cytokine genes, especially interleukin–2, which play a major role in 
activation, differentiation and proliferation  a T cells. 
 
 
 
 
5 
 
 
CALCINEURIN INHIBITORS-MECHANISM OF 
ACTION 
In cytoplasm, cyclosporine binds to a cis-trans-peptidyl-prolyl-
isomerase. Which was important in, folding proteins and peptides in to 
their native conformation (Immunophilin-protein that binds 
immunosuppressive agent: cyclophillin binds cyclosporine; FK-binding 
protein binds tacrolimus and rapamycin)1. Calcineurin-Immunophilin 
complex (i.e, cyclosporine- cyclophilin, tacrolimus – FK binding protein) 
binds to a calcium and calmodulin dependent phosphatase calcineurin. 
Which  plays crucial role in transduction of calcium dependant signal.  
Calcineurin, a phosphatase enzyme, which normally 
dephosphorylate the cytosolic part of nuclear factor of activated T cells in 
order to its entry into nucleus2 and combined with nuclear part of 
activated T cells, which activates the promoter region of Interlukin L-
2(IL-2) leading to its transcription3, which results in reduction in its 
production, expression on cell surface and the resultant reduction in T 
cell activation and proliferation. Apart from its reduction in Interlukin-2 
production, it also impairs the transcription  of  Interlukin-4(IL-4), 
Interferon(IFN)-gamma and tumour necrosis factor(TNF)-alpha.  
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The  transcription  of  other  genes,  such  as  CD-40  ligand  and  the  
proto  oncogenes  H-ras  and  C-myc  is  also  impaired.  The  stimulation  of  
proto oncogene may be relevant to the cause of certain post transplant 
neoplasia.  
Cyclosporine enhances the mRNA expression of Transforming 
Growth Factor (TGF)-beta in activated T cells4 and constrain new DNA 
Synthesis. Patients on cyclosporine were found to have higher level of 
TGF-beta than patients on other immune suppressive drugs. TGf-beta 
inhibits IL-2 dependent,  T Cell activation, and suppress the antigen 
specific T Cell proliferation. TGF-beta type 1 was a prosclerotic which 
play a major role in chronic cyclosporine nephrotoxicity. Cyclosporine 
apart from increasing TGF-beta, it increases the expression of its receptor 
in mesangial cells and activates the production of plasminogen activator 
inhibitor and fibronectin. Islem et al showed that anti TGF-beta 
antibodies prevents the certain changes of cyclosporine induce chronic 
nephrotoxicity. Thus the TGF-beta had the immunosuppressive role on its 
own and mediates immune suppressive effects of cyclosporine.  
Thus  the  TGF-beta  may  play  a  central  role  in  mediation  of  
beneficial and detrimental effects of calcineurin inhibitor. Dentritic cell 
plays a major role in antigen presentation. Cyclosporine inhibits its 
migration,   maturation, and impairs its antigen presenting capabilities5. 
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CYCLOSPORINE 
Cyclosporine is a small cyclic polypeptide of 11 amino acids in 
position 1, 2, 3, & 11 and molecular weight of 1200Kd. The cyclic 
polypeptide structure was necessary for its action. Cyclosporine is soluble 
only in lipids and organic solvents. First isolated by the department of 
microbiology at Sandoz (Switzerland) from two strains of imperfect 
fungai Cylindeocarpon  lucidum booth and Trichoderma polysporum rifai 
as  an antifungal agent6.  
Formulations  
 Cyclosporine available in oral and intravenous preparations. The 
original oil based sand-immune preparation had been replaced by 
microemulsion(Neo-oral). The oral preparation available in solution and 
soft gelatin capsules. Oral sand immune prepararion has variable time to 
peak(Cmax) concentration but averages 4 hours. Second peak appears in 
substantial portion of transplant patients. The oral bioavailability of 
cyclosporine was better. The peak cyclosporine level(Cmax) was higher 
and trough(Co) concentration correlates better with the systemic exposure 
as reflected by the area under the curve(AUC). Generic formulations of 
cyclosporine were available. FDA approved the generic formulations. But 
because of its varied absorption and narrow therapeutic index the 
bioequivalence stantardization of FDA for cyclosporine was more 
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rigorous. While changeover from branded to generic formulations, the 
drug level monitoring should be intensified. Since the pharmacokinetics 
and bioequivalence were different for sand immune and neo-oral its 
generic formulation should not be interchanged. Cyclosporine absorption 
was delayed and decreased by food. High and low fat meals decreases the 
area under the curve by 13% and maximum concentration by 33% when 
it consumed with in thirty minutes of drug intake. Cyclosporine 
distributed extensively in extra vascular compartment, at steady state the 
volume of distribution was 3-5L/Kg in kidney transplant recipients after 
Intra venous dosing. 
Factors determining absorption 
 Individual patient 
 Type of transplant 
Transplant age 
Bile flow 
Gastro Intestinal motility state 
Type of formulations 
Distribution 
In blood, one third was  bound to lipoproteins in plasma, remaining 
two third found in RBCs. So the whole blood levels were higher than 
plasma. Cyclosporine which bound with lipoproteins were easily enters 
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plasma membrane. Hence hypo cholesterelemia exaggerates toxicity and 
heper cholesterelemia reduces its toxicity. Hyperlipidemia was due to its 
affinity towards LDL receptor.  
Metabolism 
 Cyclosporine was extensively metabolized by cytochrome P 450 
3A in liver and gastrointestinal microsomal enzyme system6. It 
underwent first pass metabolism in liver and gastrointestinal tract by 
cytochrome P 450 3A and P-glycoprotein. The variability in its 
metabolism among individual was due to polymorphism7 in cytochrome P 
450 3A and P-glycoprotein. More than twenty metabolites of 
cyclosporine had been identified in bile, blood, feces and urine. 
Metabolites were inactive when compared to parent drug. Six percent of 
metabolites were excreted in urine. Only 0.1% of cyclosporine was 
excreted unchanged in urine.  Since cyclosporine was neither excreted in 
urine nor removed by dialysis dose modification does not required in 
renal dysfunction. Cyclosporine was secreted in breast milk but in 
smaller quantity. Majority of its metabolites excreted through bile by 
liver, hence dose modification  was imperative in liver disease. Half life 
was biphasic,  averages 8.4-27 hours(range 4-50).  
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TACROLIMUS 
 Tacrolimus was a macrolide immuno suppressant isolated from 
fungus Streptomyces tsukubaensis in 1994 from Japan8.  It  was  a  23  
membered macrolide lactone. It was a neutral and hydrophilic compound. 
Initially it was used in liver transplant only. Approved by a FDA for 
kidney transplant in 1997, within a decade of approval its use had been 
raised to 67% in kidney transplant because of its potential immuno 
suppressive action. 
Absorption 
 Tacrolimus absorption was variable. Bio availability varies from 
5% to 95% (mean 25%). Reasons for reduced absorption were 
african/non-caucasians, diabetic patients and fatty food. Peak 
concentration attained after 0.5-1 hour. While took with food peak 
concentration delayed by 50-25% and the area under curve decreased by 
25-40%. In intestine absorbed tacrolimus was metabolized by CYP P 450 
3A, extruded into intestinal lumen by P-glycoprotein. Extruded drug 
again get  reabsorbed9. Bile is not essential for tacrolimus absorption. 
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Distribution 
 In blood, tacrolimus was intensively bound to erythrocytes. Whole 
blood drug concentration significantly higher (4-14 time) than 
corresponding plasma level. In plasma most of the drug bound with 
alpha1 acid glycoprotein, globulin and albumin. In pediatric recipients a 
volume of distribution was higher than adult, because of increased 
permeability of membrane and reduced quality and affinity to plasma 
protein. 
Metabolism 
  Tacrolimus was extensively metabolized by cytochrome P  450 
3A4 in liver and intestinal epithelial cells by hydroxylation and 
demethylation. Metabolism of tacrolimus was highly variable because of 
cytochromeP 450 3A4 polymorphism. Expression of cytochrome P 450 
3A4 varied from 10-100 fold in liver and 30-40 fold in intestine. The 
metabolites were one-tenth as active as tacrolimus. Its  metabolites were 
seen in urine, feces and bile. 
Elimination 
 More than 95% of tacrolimus was eliminated in bile10. Cholestasis 
increases the drug level. Urinary excretion accounts for 2.4%. 
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Factors affecting the pharmacokinetics of tacrolimus 
Special patient population 
 In renal transplant,  tacrolimus clearance was higher among live 
related kidney transplant recipient than cdaver transplant recipient 
because of low haematocrit and albumin. Diabetic patients shown 38% 
reduction in area under curve because of altered gut motility. Cystic 
fibrosis patients with pancreatic involvement in need of 40% higher dose 
because of decreased absorption due to pancreatic enzyme deficiency. 
Hepatic dysfunction 
 Tacrolimus clearance was reduced up to 2-3 fold in patients with 
liver dysfunction. In hepatitis C virus infection  drug level was higher 
because of alrtered cytochrome P system.  
Renal function 
  Tacrolimus clearance was not altered by renal dysfunction and 
dialysis. 
Age 
 Children required higher dosage because of differences in 
cytochrome P 450 3A, bowel length and P glycoprotein expression. 
Sex 
 No difference between sex. 
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Race 
 African requires more dose than caucasians due to differences in 
expression of cytochrome P4503A and P glycoprotein expression in 
intestine and liver. 
Haematocrit and albumin: 
 Reduction in haemotocrit and albumin results in lesser 
concentration of drug  in whole blood. 
Diurnal variation 
 Area under curve after morning dose was more than area under 
curve after night dose because of circadian effect on gastric emptying 
time and gastro intestinal perfusion. 
Food  
Effect of food depends on fat contents of food. Low fat content 
may delay the C-max. 
Steroid 
 Steroid may induce cytochrome P 4503A and tacrolimus 
metabolism. 
Diarrhea 
 Increased tacrolimus level because of loss of P glycoprotein which 
prevent extrusion of drug  from gastro-intestinal epithelial cells. 
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PHARMACOGENETICS OF CALCINEURIN 
INHIBITORS(CNI) 
Variability in cyclosporine Pharmacokinetics among individual 
was due to variability in exposure and function of cytochrome  P 450 
3A4 and P glycoprotein polymorphism11. P-glycoprotein polymorphism 
was due to ABCB1 gene Polymorphism. P-glycoprotein, a membrane 
protein found on membrane, act as exporter of intracellular xenobiotics, 
which is ATP dependent. In kidney P glycoprotein expressed on the 
luminal surface of proximal and distal tubular epithelial cells. 
Cyclosporine act as substrate for P glycoprotein, so if there is any defect 
in expression or function of P glycoprotein due to ABCB1 gene 
polymorphism cyclosporine  accumulate inside the cell and lead on to 
nephrotoxicity12. According to Anglichem et al, sirolimus and 
cyclosporine competes for P glycoprotein. So if used in combination 
sirolimus cause cyclosporin accumulation and nephrotoxicity. 
 Transcriptional analysis revealed that epithelial mesenchymal trans 
formation(EMT) and  endoplasmic reticulum stress are the two main 
mechanism which cause CNI nephrotoxicity. In vitro studies revealed 
that cyclosporine induced EMT changes in proximal tubular epithelial 
cells through TGF-beta up regulation. Vimentin expression had been 
increased in rats treated with cyclosporine. 
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 Endoplasmic reticulum stress is due to accumulation of mis-folded 
proteins within endoplasmic reticulum. It has been proved by in vitro 
studies. Progress in whole genome studies, molecular biology and 
functional genetics will throw further light on this area in future. 
 
CALCINEURIN INHIBITORS-DRUG INTERACTION 
Cyclosporine was degraded by hepatic cytochrome P450. Durgs 
which enchances the ability of  cytochrome P450 reduces the 
concentration of cyclosporine and drugs that inhibit the cytochrome P450 
increases the concentration of cyclosporine level13  in blood. 
Durgs that decreases the calcineurine level (cytochrome P450 
inducer): 
 Anti tuberculous drugs 
  Rifampicin ( marked reduction ) 
  Pyrizinamide  
  Ethambutol 
 Anticonvulsants 
  Barbiturates (marked reduction ) 
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  Phenytoin       
  Primidone  
  Carbamazepine (mild reduction) 
  Modafinil (mild reduction) 
  Oxcarbazepine (second generation – mild reduction) 
Antibiotics: 
 Nafcillin 
 Intravenos trimethoprim 
 Intravenos sulphadimidine. 
 Imipenem 
 Cephalosporin 
 Terbinafine 
Others: 
 St.John’s wort (Hypericum perforatum) – Herbal anti 
depressant  
 Ticlodipine. 
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 Corticosterods 
Drugs that increases calcineurin level(cytochrome P450 
inhibitor): 
Calcium channel blocker: 
  Verapamil (40% reduction in CNI dose) 
  Diltiazem (40% reduction in CNI dose) 
  Amlodipine  
  Nicardipine  
  Nifedepine (minimal effect) 
  Felodipine (minimal effect) 
Anti fungal  
 Ketoconazole (80% reduction of CNI dose) 
 Fluconazone 
 Itraconazole 
 Voricanozole 
Antibiotics: 
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 Erythromycin 
 Clarithromycin 
 Azithromycin (conflicting reports) 
Anti retroviral  drugs: 
 Protease inhibitor (Ritonavir) 
Hormones: 
 Oral contraceptive 
 Anabolic steroids 
 Testosterone 
 Nor ethisterone 
 Danazol 
 Somatostatin 
Other drugs: 
 Amiodarone 
 Carvedilol 
 Allopurinol 
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 Bromocriptine 
 Chloroquine 
Grape fruit juice (cytochrome P450 inhibitor) 
Drugs that increases absorption: 
 Metoclopromide 
 Grape fruit juice 
Drugs that exaggerates CNI nephrotoxicity. 
 Potentially nephrotoxic drugs should be avoided while patient on 
calcineurine inhibitor. Can be used with appropriate monitoring  
 Amphotericin 
 Aminoglycoside 
 NSAID 
 ACEI / ARB 
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CALCINEURIN INHIBITORS TOXICITY 
 Despite the advantages of calcineurin inhibitors in solid organ 
transplantation and other diseases, its side effects hampers the long term 
graft and recipient morbidity and mortality14.  
 Renal   
  Acute calcinurin inhibitor nephrotoxicity 
  Chronic calcinurin  inhibitor nephrotoxicity 
 Hepatic   
 Neurologic  
 Cardiovascular  
 Dermatologic  
 Dental  
 Metabolic  
  Lipid abnormality  
  New Onset Diabetes Mellitus 
  Hyperuricemia and Gout 
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 Infection and malignancy 
 Thromboembolism  
Renal toxicity 
 Acute calcineurin inhibitor nephrotoxicity 
  Acute arteriolopathy   
Tubular isometric vacuolization 
  Thrombotic microangiopathy 
 Chronic calcineurin inhibitor nephrotoxicity 
  Interstial fibrosis and tubular atrophy (typically stripped) 
  Medial arteriolar hyalinosis 
  Glomerular capsular fibrosis 
  Global glomeruloselerosis 
  Focal segmental glomerulo sclerosis 
  Juxta glomerular apparatus hyperplasia 
  Tubular micro calcification  
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Nephrotoxicity was the major side effect of these drugs. Initial 
experiences revealed that it was reversible hemodynamic changes. In 
1984 Meyers et al demonstrated that progressive and irreversible changes 
also occurs in kidney resulting in tubular and interstial injury and 
glomerulosclerosis. The reversible changes were known as acute 
calcineurin inhibitor nephrotoxicity. Irreversible changes were known as 
chronic calcineurin inhibitor nephrotoxicity 
Acute arteriolopathy (vascular effect) 
 In 1985, Murray et al shown that afferent arteriolar constriction15 
was caused by cyclosporine, which result in acute reversible functional 
impairment of glomerular filtration. This is due to imbalance between 
vasoconstrictor and vaso dilator substances produced by cyclosporine 
(vasoconstrictor : endothelin, rennin angiotensin ; vasodilator : 
prostacyclin, prostaglandin E2, nitrous oxide) and free radical formation. 
Endothelin was a potent vaseconstrictor widely released in the kidney and 
vascular bed. The role endothelin in acute reversible vasoconstriction was 
established by the obliteration of these vasoconstrictive effect by anti 
endothelin antibodies16. Apart from direct afferent arteriolar 
vasoconstriction it also stimulates the  rennin angiotensin  system by 
recruiting rennin secreting cells in juxta glomerular apparutus and results 
in increased rennin production. Rennin enhances angiotensin II and 
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reduces blood flow. Thus it becomes vicious cycle. On chronic use of 
cyclosporine it results in juxta glomerular  cells hyperplasia. The 
molecular mechanism by which cyclosporine recruits the renin secreting  
cells in afferent arterioles and increases renin secretion was currently not 
known. Cyclosporine and tacrolimus inhibits endothelium mediated 
nitrous oxide synthesis thus by inhibits vasodilation. Cyclosporine  
induced vasooclusion results in hypoxia, free radical formation and super 
oxide production. By farming peroxynitrite, super oxide decreases nitrous 
oxide bio availability.  
Tubular effects (toxic tubulopathy) 
 Histologically isometric vacuolization17 in tubular epithelial cells 
by cyclosporine was due to enlargement of endoplasmic reticulum and 
increased lyzosomes. These vacuolization was found with cyclosporine 
and tacrolimus in the absence of renal dysfunction. Renal dysfunction 
may found in the absence of morphological feature. Recent studies 
revealed that these vacuolization also occurs in renal ischemia (on tubular 
epithelial injury due to intra venus administration of hyper osmotic fluid 
(manitol, inulin, glucose). These vacuoles were varying in size (in 
contrast to calcineurin induced) and called as osmotic nephrosis. Apart 
from ischaemic insult direct role of calcineurin inhibitors also postulated, 
inclusion bodies were also expressed as on tubular epithelial cells, which 
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are nothing but giant mitochondria and auto lysozomes. Even though 
mechanism of inclusion body formation was not known the important 
effect of cyclosporine on mitochondrial function was proved. How ever 
inclusion bodies also found in ischemic injury and preimplantation donor 
biobsies.  
Thrombotic microangiopathy 
It was a distinct form of calcineurin inhibitor nephrotoxicity, 
uncommon but serious histopathologically characterized by intra 
capillary platelet thrombi, intimal wall thickening, necrosis and luminal 
occulusion. This lesions may in patchy distribution and variable severity. 
Mechanism postulated was endothelial damage caused by ischemia due 
to direct calcineurin inhibitor effect on endothelium. The concomitant 
increased platelet aggregation, plasminogen activator inhibitor activity 
and pronecrotic activity of calcineurine inhibitor on endothelium 
eventually lead to development of thrombotic micro angiopathy.  
Chronic CNI nephrotoxicity 
 Calcineurin inhibitors not only induces acute reversible 
nephrotoxicity but associated with chronic reversible nephrotoxicity, 
which involves vessels (arterial hyalinosis), interstitium (interstitial 
fibrosis & tubular atrophy) and glomeruli (focal segmental glomerulo 
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selerosis, thickening & fibrosis of bowman’s capsule). Nankivell et al 
shown that 15 years after transplantation lesions suggestive of 
irreversible damage were seen in all recipient. However these features 
were may be due to rejection, infection, hypertension, diabetes mellitus, 
drugs and aging. Since this study did not have control arm. Cycloscorin 
related haemodynamic changes and direct toxicity was thought to play a 
role. 
Vascular effect 
 Afferent arterioles nodular hyalinosis was regarded as a hall-mark 
of CNI nephrotoxicity. Which was due to replacement of reactive smooth 
muscle cells by focal or circular protein (hyaline) deposits at the 
peripheral part of afferent arteriole wall, eventually results in narrowing 
of afferent arteriolar lumen. The molecular mechanism behind this was 
not well elucidated. 
Tubulo-interstitial effect 
 Cyclosporine induced luminal narrowing, hypoperfusion, hypoxia 
and formation of reactive oxygen species results in cell death by 
apoptosis. Catalase, a enzyme which catalyse reactive oxygen species, 
antagonize the effects of cycloscorine induced apoptosis in vitro. Second 
hypothesis was the direct injury to the epithelial cell by cycloscorine 
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which results in accumulation of intra-cellular reactive oxygen species, 
lipid peroxidation products along with an altered glutathione redox state. 
Cyclosporine induced upregulation of TGF – beta play a major role 
in the formation of chronic interstitial fibrosis and tubular atrophy. TGF – 
beta promotes interstitial fibrosis by increasing the production of extra 
cellular matrix protein and decreasing the degradation. In addition TGF - 
beta promotes epithelial mesenchymal transition, which results in loss of 
epithelial phenotype. Which results in  loss of epithelial polarization, 
denovo expression of dysregulated  acting over smooth muscle, loss of 
intercellular adhesion through down regulation of E-cathedrin, 
destruction of basement membrane and increased cell invasiveness. 
Remuzzi et al shown that hyper aldosteronism secondary to salt depletion 
and RAS activation increases the production of TGF – beta and reactive 
oxygen species, which cause interstitial fibrosis. Apoptosis of tubular and 
interstitial cells aggravated by direct toxic effect of CNI on apoptosis 
gene. In addition cyclosporine competitively inhibit the P-glycoprotein 
on luminal side of tubular epithelial cells and cause accumulation of toxic 
substances inside the cell. 
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Glomerular effects 
 Chronic CNI intake results in glomerulosclerosis secondary to 
ischaemia induced by arterial hypertension. Tubular damage results in 
atubular glomeruli which was shrunken in size and shows periglomerular 
fibrosis. In addition CNI can cause secondary focal segmental 
glomerulosclerosis due to either arteriolar hyalinosis or global 
glomerulosclerosis. 
Non specificity of histlogic findings  
Morphological findings in CNI toxicity were not specific to CNI. It 
also found in other diseases. So called specific lesions such as tubular 
vacuolization and arterial hyalinosis also seen in other diseases.  
Hypertension 
 Impaired renal haemodynamics due to afferent arteriolar 
vasoconstriction by CNI results in sodium, water retention and 
hypertension. In addition stimulation of sympathetic system, activation of 
RAS and suppression of atrial natriuritic peptide impairs the diuretic and 
natriuretic response to volume overload. Hypertension was tend to be less 
marked  in  tacrolimus  on  comparison  with  cyclosporine  primarily  due  to  
less peripheral vasoconstriction. 
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Hyperkalemia 
 Hyper/normokalemia, mild hyperchloremic acidosis and patients 
intact  ability to secrete acid urine was usual features of CNI toxicity. It 
was due to inability to excrete acute potassium load due to defect in 
production of aldosterone or to its post receptor response. Exaggerated by 
concomitant acetyl choline esterase inhibitors, angiotension receptor 
blocker. 
Hypomagnesemia & hypocalcemia  
 It was due to increased urinary loss in patients on CNI due to down 
regulation of specific transport proteins. 
Hyperuricemia 
 Impaired uric acid secretion due to cyclosporine induced direct 
tubular defect which may lead on to gout. 
Hepatic 
 Mild transaminites and mild hyper bilirubenemia may occur in 
50% of patients on cyclosporine, due to defect in bile secretion, there 
may be any morphological changes. Cyclosporine use was associated 
with cholelithiasis due to increased lithogenecity. Gastro intestinal side 
effects such as anorexia, nausea, vomiting, diarrhea and abdominal 
discomfort occurs more with tacrolimus than cyclosporine. 
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Neurologic 
x Coarse tremor, dysesthesia, headache, insomnia (dose and blood 
level related)  
x Cognitive impairment coinciding with peak drug level. 
x Occasional seizure, full blown leukoencephalopathy and bone pain. 
x Disabling pain, hallucination, seizure, cerebellar ataxia and motor 
weakness. 
Dermatological 
x Hypertrichosis – obvious in dark haired girls. 
x Eye brow prominence 
Dental 
Gingival hyperplasia due to fibroblast proliferation and collagen 
deposition was common in cyclosporine and exaggerated by poor oral 
hygiene and concomitant calcium channel blocker. Severe gingival 
hypertrophy may require gingivectomy and switch to tacrolimus  
Metabolic 
Glucose intolerance 
 Impaired glucose tolerance and new onset diabetes mellitus was 
more common with tacrolimus than cyclosporine, reason being the more 
concentration of FK binding protein than cyclophilin in islets,. Steroid 
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may exaggerate the cyclosporine induced glucose intolerance. Glycosuria 
may be result in direct cytoplasmic injury to tubules. Risk factors were 
obesity, family history of diabetes and hepatitis C virus. 
Hyperlipedemia 
 Cyclosporine was implicated in post transplant 
hypercholesterolemia. The mechanisms were LDL receptor binding  by 
cyclosporine, defective LDL feed back control by liver and altered bile 
acid synthesis. 
Hyperuricemia 
 Cyclosporine induced tubular injury results in impaired uric acid 
secretion which results in accumulation of uric acid in blood and gout. It 
was aggravated by concomitant diuretic use.  This was more with 
cyclosporine than tacrolimus. 
Infection and malignancy 
 Infections and malignancies were inevitable following 
immunosuppressant use in organ transplantation. Infection more 
coincides with level of drugs in blood. More incidence of skin cancer had 
been reported with cyclosporine use. Cyclosporine can promote tumor 
progression,  which  was  independent  of   its  effects  on  the  immune  
response.  
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MONITORING OF CALCINEURIN INHIBITORS 
Monitoring of cyclosporine level was essential, due to inter and 
intra patient variability, lower level results in rejection, higher lever 
results in toxicity, co prescribed drugs may result in alteration of 
cyclosporine level. Recovery from uraemia in early post transplant period 
results in increasing absorption so it needs close monitoring. Because of 
availability of various assay methods, option of multiple matrices 
(plasma, whole blood) and variable correlation with time of drugs intake 
results in much confusion. 
Trough monitoring 
Even though monitoring at the trough, before administering next 
dose (Co level) was traditional and convenient, the efficacy was 
questionable. Area under curve calculation using multiple blood sample 
assessment will be more effectively reflect the exposure of patient to 
drugs. Correlation with nephrotoxicity was not linear.  Correlation with 
episode of acute rejection was also poor18. 
Area under curve(AUC) 
Even though calculation of AUC by assessing multiple blood 
samples in 0-12 hrs was more accurate, the process was largely 
impractical.  Gaspais  et  al  shown  that  AUC  by  1,  5,  8  &  11hrs  sample  
allowed accurate monitoring. Malhati et al shown that since 
microemulsion form of cyclosporine absorption variability limited to first 
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four,  the AUC 0-4 hrs, will correlate with clinical outcomes. But, it also 
requires multiple sampling. So the ideal strategy should be single point 
measurement. Monitoring two hours level (C2) was considered an ideal 
surrogate marker20. 
Two hours monitoring 
Most  accurate  one  point  prediction  of  AUC  0-4  hrs,  was  the  C2 
level  (sample  taken  two  hours  after  last  dose)  and  it  showed  less  
variability  than  either  Co  or  C1 according to international renal 
transplantation study group. Canadian neoral renal transplantation study 
group’s result shown that C2 level of more than 1500 micro gram per liter 
at 2 weeks of post transplant period correlate significantly with lower 
rejection rates. According to Helsinki groups the rate of acute rejection 
was not significantly influenced by either C0 or  C2.  C2 Monitoring 
allowed a dose reduction in 34% of patients compared to 14.3% of 
patients in Co monitoring. In spite of dose reduction there was no 
improvement in renal function during 40 months follow up. Despite those 
controversial issues at the moment, trough (C0) remain the standard 
method of monitoring. 
Cyclosporine assays: 
High perfusion liquid chromatography(HPLC) method: 
 Despite the availability of several methods to measure the 
Cyclosporine level HPLC was the gold standard, because of its ability to 
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measure parent compound only. However it was expensive, labour 
intensive and not available in all centers. Its accuracy in lower plasma 
level was less précised. 
Immunoassay: 
1. Non specific polyclonal immunoassay. 
2. Non specific monoclonal immunoassay. 
Immuno assay are based on monoclonal / polyclonal anti bodies 
against cyclosporine. Monoclonal immune assay were largely replaced 
HPLC because it can be done on automated chemistry analyzers.  
Fluorescence Polarization Immune Assay was the most common 
immune assay used now a days. But it overestimate by 45% because 
significantly cross reacts with cyclosporine metabolites. 
Rapid Liquid Chromotography – mass spectrometry method was a 
newer method, which had been used in oxford laboratory, which 
eliminate  the  low  precision  of  immune  assay  in  lower  level  of  
concentration. 
 
 
 
 
Materials and 
Methods 
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MATERIALS AND METHODS 
Study design:    Prospective study. 
Inclusion criteria:  
All end stage renal disease patient who underwent renal 
transplantation between June 2012 and June 2013 in the department of 
nephrology, Rajiv Gandhi government general hospital were included. 
Exclusion criteria: 
 Patients who had Graft dysfunction due to surgical issues, who 
underwent graft nephrectomy, who expired  were excluded. 
Eligible patients were  enrolled. Their demographic profile such as 
age, sex, type of native kidney disease, type of donor whether live related 
or deceased,  age and sex of donor, type of relation in case live related 
were collected. In immediate post operative period if the patient have 
raising creatinine,  complete blood count, peripheral smear study, platelet 
count, serum lactic dehydrogenase,  urine analysis, serum electrolytes, 
liver function test, urine and blood culture sensitivity  were done. USG 
KUB, Renal Doppler and necessary investigations were  done in order to 
rule out surgery related complication.   
Whole blood cyclosporine/tacrolimus  trough(CO) level was 
assayed twelve hour after previous dose If the renal dysfunction does not 
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due to surgical complication and patient showed clinical feature of 
Calcineurin toxicity such as tremor, paresthesia, hypertension(worsening 
hypertension in need of more drugs and new onset hypertension), 
paresthesia, gum hypertrophy, hypertrichosis, sodium, potassium, 
cholesterol  were done. 
 In this study cyclosporine trough level was assayed by enzyme 
linked microparticle immune assay(EMIA) and tacrolimus trough level 
was assayed by chemiluscent enzyme linked immune assay(CLEIA). 
As per our department protocol for those receive induction 
treatment cyclosporine level was considered in therapeutic range if it was 
200-250ng/ml at 0-1month, 100-200 ng/ml at 2-6 months, and around 
100  ng/ml  after  6months.  For  tacrolimus,   the  level  was  considered  in  
therapeutic range if it was around 8 ng/ml at 0-1 month, 5-6 ng/ml at 3-
6months,  3-5  ng/ml  after  6months.  For  those  didn’t  receive  induction,  
cyclosporine level was considered in therapeutic range if it was 200-
250ng/ml at 0-1month, 150-200ng/ml at 2-6 months, and around 100-150 
ng/ml after 6months. For tacrolimus, the level was considered in 
therapeutic range if it was around 8-10ng/ml at 0-1 month, 7-8ng/ml at 3-
6months, around 5ng/ml after 6months      
 
Results  and 
Analysis 
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RESULTS 
 This study was conducted in our department among End Stage 
Renal Disease patients who underwent Renal Transplantation from June 
2012 to June 2013. A total of sixty one patients were included out of 
seventy five. Of which males were 83.6% (51) and females were 16.4% 
(10), (Table 1).  
Table 1 
Recipient sex 
Sex No % 
Male 51 83.6 
Female 10 16.4 
 
 
83.6
16.4
Sex of Recipient
Male Female
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Among Recipients majority of them were in 3rd decade 39.3% (24), 
followed by equal proportion in 4th 24.6% (15) and 5th decade 24.6% 
(15), (Table 2). Mean age was 31.45(range: 17-56years). 
Table 2 
Recipient age group in years 
Age group No % 
10-19 3 4.9 
20-29 24 39.3 
30-39 15 24.6 
40-49 15 24.6 
50-59 4 6.6 
 
 
 
0
5
10
15
20
25
30
35
40
10-19 20-29 30-39 40-49 50-59
4.9
39.3
24.6 24.6
6.6
Recipient age group in years
38 
 
70.5% patients were live related donor recipients and 29.5% were 
deceased donor recipients. (Table 3). 
Table 3 
Type of Donor 
Type of donor No % 
Live donor 43 70.5 
Deceased donor 18 29.5 
 
Among live related donor males were 16.7% (7) and females were 
83.3% (36) (Table 4). 
Table 4 
Sex Ratio of Live Donor 
Sex No % 
Male 7 16.7 
Female 36 83.3 
 
Of which mothers were 44.2% (19), followed by spouse 
30.2% (13), fathers 16.3% (7) and sisters 9.3%(4), (Table 5). 
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Table 5 : Relationship among Live donor  
Relation No % 
Father 7 16.3 
Mother 19 44.2 
Spouse 13 30.2 
Sister 4 9.3 
  
 
 
 
 Among deceased donor males were 19.4% (17) and females were 
5.6% (1), (Table 6). 
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Table 6 
Deceased donor sex 
Sex No % 
Male 17 19.4 
Female 1 5.6 
 
 
 After renal transplantation recipients were treated with 
immunosuppressive agents [three drugs : calcineurine Inhibitors 
(cyclosporine / Tacrolinus) + mycophenolate Mofetile / Azathioprine + 
Steroids] as per our department protocol. Induction treatment was given 
as per our department protocol [rabbit Anti Thymocyte Globulin / 
Interleukin – 2 receptor Antagonist) for high risk recipients such as those 
received organ from deceased donor, spouse donor and second 
transplant). These patients were followed up for 0-18 months (mean 12.5 
19.4
5.6
Deceased donor sex
Male Female
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months) for calcineurin inhibitor toxicity. Observed toxic features were 
grouped into 0-3, 3-6, 6-9 and more than 9 months of post transplant age.  
Follow up revealed that toxicity of calcineurin inhibitors were 
clinically present in 60.7% (37) in 0-3, 39.3% (24) in 3-6,  25.4%(15) in 
6-9 months and 23.3%(10) in more than 9 months(Table 7). 
Table 7 
Clinical CNI toxicity  
Clinical 
toxicity 
0-3 months 3-6 months 6-9months >9months 
n % n % n % n % 
Yes 37 60.7 24 39.3 15 25.4 10 23.3 
No 24 39.3 37 60.7 44 74.6 33 76.7 
 
 
 Among them, further toxicity profile was evaluated and grouped 
into 0-3, 3-6, 6-9 and >9 months. Evaluated toxicity profile were tremor, 
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paresthesia, hypertension(new onset /worsening), hypertrichosis, gum 
hypertrophy and NODAT(based on ADA guidelines) (Table 8). 
Table 8 
CNI Toxicity Profile 
 0-3 months 3-6 months 6-9months >9months n % n % n % n % 
Tremor Yes 24 39.3 21 34.4 15 25.4 9 20.9 No 37 60.7 40 65.6 44 74.6 34 79.1 
Paresthesia  Yes 2 3.3 1 1.6 0 0 0 0 No 59 96.7 60 98.4 59 100 43 100 
Hypertension  Yes 24 39.3 19 31.1 8 13.6 3 7 No 37 60.7 42 68.9 51 86.4 40 93 
Hypertrichosis Yes 0 0 0 0 1 1.7 3 6.9 No 61 100 61 100 60 98.3 40 93.1 
Gumhypertrophy Yes 0 0 0 0 1 1.7 1 2.3 No 61 100 61 100 60 98.3 40 97.7 
NODAT Yes 3 4.9 3 4.9 4 6.8 1 2.3 No 58 95.1 58 95.1 55 93.2 42 97.7 
 
Percentage of patients with CNI toxicity 
 
 Tremor was present in 39.3% (24) in 0-3 months, 34.4% (21) in 
3-6 months, 25.4% (15) in 6-9 months and 20.9% (9) in more than 9 
months.  Hypertension was present in 39.3% (24) in 0-3 months, 31.1% 
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(19) in 3-6 months, 13.6% (6) in 6-9 months and 7% (3) in more than 9 
months. Hypertrichosis and gum hypertrophy were present in few 
patients after 6 months of transplant.  NODAT was present in 4.9% (93) 
in 0-3 months and 3-6 months, 6.8% (4) in 6-9 months and 2.3% (1) in 
more than 9 months. 
 During follow up improvement in graft dysfunction following 
tapering with calcineurin inhibitor was presumed to be due to calcineurin 
inhibitor toxicity after excluding rejection. Table 9 showed that graft 
dysfunction due to calcineurin inhibitor toxicity.  
Table 9 
Graft dysfunction 
 0-3 months 3-6 months 6-9 months >9 months 
 n % n % n % n % 
Yes 23 37.7 14 23 22 37.3 3 7 
No 38 62.3 47 77 37 62.7 40 93 
 
 
 Graft dysfunction was in 37.7% (23) in 0-3 months, 23% (14) in 3-
6 months, 37.3% (22) in 6-9 months, and 7% (3) in more than 9 months. 
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 Whole blood trough(Co) level was done. Which shown in  
Table 10.  
Table 10 
Trough (Co) level 
 0-3 months 3-6 months 6-9 months >9 months 
 n % n % n % n % 
Elevated 
CO  
18 29.5 17 27.9 19 32.2 8 18.6 
Normal Co 43 17.5 44 72.1 40 67.8 35 81.4 
 
 
Elevated trough level was seen in 29.5% (18) in 0-3 months, 27.9% 
(17) in 3-6 months, 32.2% (19) in 6-9 months and 18.6% (8) in more than 
9 months. 
 Biopsy and histopathological examination was done only in small 
number of patients because of its invasiveness and procedure related 
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complication, patient willingness and improvement with tapering of 
drugs. Biopsy features were shown in Table 11.  
 
Table 11 
Histopathological features of CNI toxicity  
 0-3 months 
3-6 
months 
6-9 
months >9 months 
 No % No % No % No % 
Iso.vacuolization 6 9.8 5 8 2 3.4 0 0 
Med. Hyalinosis 2 3.3 1 1.6 0 0 0 0 
TMA 1 0 0 0 0 0 0 0 
Glomerulosclerosis  0 0 0 0 0 0 0 0 
Intertial fibrosis 0 0 1 0 0 0 0 0 
Tubular atrophy 0 0 1 0 0 0 0 0 
CNI Toxicity 6 9.8 5 8.2 2 3.4 0 0 
 
In 0-3 months Six patients were found to have histopathological 
features of CNI toxicity. Isometric vacuolization was found in all 
biopsies, medullary hyalinosis and thrombotic microangiopathy were 
seen in two and one of those biopsies. In 3-6 months 5 patients shown 
histopathological evidence of CNI toxicity of which isometric 
vacuolization was present in all five biopsies and medullary hylinosis 
present in one biopsy. In 6-9 months, 2 patients were shown evidence of 
histopathological toxicity, isometric vacuolization was present in both of 
them. 
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ANALYSIS 
 Statistical analyses were done by SPSS 20.6 software. Analysis 
was done in each post transplant age group. Factors analyzed were trough 
(Co) level (elevated trough (Co) level / normal trough (Co) level) versus 
clinical toxicity, tremor, paresthesia, hypertension, NODAT, graft 
dysfunction and histopathological toxicity. Hypertrichosis and gum 
hypertrophy were not analyzed because of its lower frequency in this 
study groups. 
ANALYSIS AT 0-3 MONTHS 
Clinical Toxicity vs Trough Level (0-3 months) 
  Elevated CO Normal CO P 
Clinical 
toxicity 
Present 14 23 0.077 Absent 4 20 
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Analysis revealed that no significant correlation between the 
clinical toxicity and trough (Co) level. 
 
Clinical features versus Trough (Co) level (0-3 months) 
  Elevated CO Normal CO P 
Tremor Present 10 14 0.094 
Absent 8 29 
Paresthesia Present 1 1 0.518 
Absent 17 42 
Hypertension Present 6 18 0.534 
Absent 12 25 
NODAT Present 2 1 0.148 
Absent 16 42 
 
 There is no significant correlation between tremor, paresthesia, 
hypertension, NODAT and trough (Co) level. 
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Graft Dysfunction Vs Trough (Co) level (0-3 months) 
  Elevated CO Normal CO P 
Graft 
dysfunction 
Present 7 16 0.902 Absent 11 27 
 
 
 
Analysis revealed that no significant correlation between the graft 
dysfunction and trough (Co) level. 
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Histopathological Toxicity Vs Trough (Co) level (0-3 months) 
  Elevated CO Normal CO P 
Histopathological 
toxicity 
Present 1 5 0.468 Absent 17 38 
 
 
 
Analysis revealed that no significant correlation between the 
histopathological toxicity and trough (Co) level. 
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ANALYSIS AT 3-6 MONTHS 
Clinical toxicity vs Trough (Co) level (3-6 months) 
  Elevated CO Normal CO P 
Clinical 
toxicity 
Present 13 11 0.001 Absent 4 33 
 
 
Analysis revealed that there was significant correlation between the 
clinical toxicity and trough (Co) level. 
Clinical features Vs Trough (Co) level (3-6 months) 
  Elevated CO Normal CO P 
Tremor Present 13 8 0.001 Absent 4 36 
Paresthesia Present 0 1 0.531 Absent 17 43 
Hypertension Present 7 12 0.295 Absent 10 32 
NODAT Present 1 2 0.829 Absent 16 42 
 Analysis revealed that there was significant correlation between 
tremor and elevated trough level. No significant correlation between 
paresthesia, hypertension, NODAT and elevated trough(Co) level. 
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Graft Dysfunction Vs Trough (Co) level (3-6 months) 
  Elevated CO Normal CO P 
Graft 
dysfunction 
Present 4 10 0.947 Absent 13 34 
 
 
 
Analysis revealed that no significant correlation between the graft 
dysfunction and trough (Co) level. 
 
 
Histopathological Toxicity Vs Trough (Co) level (3-6 months) 
  Elevated CO Normal CO P 
Histopathological 
toxicity 
Present 0 5 0.147 Absent 17 39 
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Analysis revealed that no significant correlation between the 
histopathological toxicity and trough (Co) level. 
ANALYSIS AT 6-9 MONTHS 
Clinical Toxicity Vs Trough (Co) level (6-9  months) 
  Elevated CO Normal CO P 
Clinical 
toxicity 
Present 11 4 0.001 Absent 8 36 
 
 
Analysis revealed that there was significant correlation between the 
clinical toxicity and trough (Co) level. 
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Clinical Features Vs Trough (Co) level (6-9 months) 
  Elevated CO Normal CO P 
Tremor Present 12 3 0.001 Absent 7 37 
Paresthesia Present 0 0  Absent 0 0 
Hypertension Present 6 2 0.005 Absent 13 38 
NODAT Present 2 2 0.430 Absent 17 38 
 
 There was significant correlation between tremor and trough level. 
No significant correlation between paresthesia, hypertension, NODAT 
and trough level. 
Graft dysfunction Vs Trough (Co) level (6-9 months) 
  Elevated CO Normal CO P 
Graft 
dysfunction 
Present 11 11 0.024 Absent 8 29 
 
 
Analysis revealed that no significant correlation between the Graft 
dysfunction and trough (Co) level. 
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Histopathological toxicity Vs Trough level (6-9 months) 
  Elevated CO Normal CO P 
HPE Present 2 0 0.37 Absent 17 40 
 
 
Analysis revealed that no significant correlation between the 
histopathological toxicity and trough (Co) level. 
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ANALYSIS AT >9 MONTHS 
Clinical Toxicity Vs Trough (Co) level (>9 months) 
  Elevated CO Normal CO P 
Clinical 
toxicity 
Present 7 3 22.72 Absent 1 32 
 
 
 
Analysis revealed that no significant correlation between the 
Clinical toxicity and trough (Co) level. 
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Clinical Features Vs Trough (Co) level (>9 months) 
  Elevated CO Normal CO P 
Tremor Present 6 3 17.36 Absent 2 32 
Paresthesia Present 0 0 0 Absent 0 0 
Hypertension Present 2 1 4.91 Absent 6 34 
NODAT Present 1 0 4.47 Absent 7 35 
There was no significant correlation between tremor, paresthesia, 
hypertension, NODAT and trough level. 
Graft Dysfunction Vs Trough (Co) level (>9 months) 
  Elevated CO Normal CO P 
Graft 
dysfunction 
Present 1 2 0.462 Absent 7 33 
 
 
Analysis revealed that no significant correlation between the Graft 
dysfunction and trough (Co) level.  
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The Correlation between clinical, trough (Co) level, graft function 
and histopathological toxicity 
 Clinical toxicity 
Elevated 
CO 
GDF Histopathological Toxicity P 
0-3 
months 37 18 23 6 3.28 
3-6months 24 17 14 5 3.81 
6-9months 15 19 22 2 2.86 
>9months 23 8 3 0 1.66 
 
 
 There was no significant correlation between clinical toxicity, 
elevated trough level, graft dysfunction, histopathological toxicity at 3-6, 
6-9 and > 9 months. 
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TACROLIMUS VS CYCLOSPORINE 
0-3MONTHS 
  Tacrolimus  Cyclosporine  P 
Tremor Present 8 16      0.046 
Absent 22 15 
Paresthesia Present 1 1 0.981 
Absent 29 30 
Hypertension Present 13 11 0.530 
Absent 17 20 
NODAT Present 3 0 0.071 
Absent 27 31 
Clinical toxicity 
Present  18 19 
0.918 
Absent 12 12 
Graft 
dysfunction 
Present  9 14 
0.222 
Absent  21 17 
Ttoxicity on 
HPE 
Present  2 4 
0.414 
Absent  28 27 
 
 There was significant correlation between presence of tremor and 
Tacrolimus at 0-3 months. But there was no significant correlation 
between tacrolimus and cyclosporine in manifestation of paresthesia, 
hypertension, NODAT, overall clinical toxicity, graft dysfunction and 
histopathological toxicity.     
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TACROLIMUS VS CYCLOSPORINE 
3-6 MONTHS 
  Tacrolimus  Cyclosporine  P 
Tremor Present 10 11 0.860 
Absent 20 20 
Paresthesia Present 1 0 0.305 
Absent 29 31 
Hypertension Present 10 9 0.717 
Absent 20 22 
NODAT Present 1 2 0.573 
Absent 29 29 
Clinical toxicity 
Present  12 12 
0.918 
Absent 18 19 
Graft 
dysfunction 
Present  8 6 
0.497 
Absent  22 25 
 Toxicity on 
HPE  
Present  1 4 
0.173 
Absent  29 27 
 
There was no significant correlation between tacrolimus and 
cyclosporine in manifestation of tremor, paresthesia, hypertension, 
NODAT, overall clinical toxicity, graft dysfunction and histopathological 
toxicity.     
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TACROLIMUS VS CYCLOSPORINE 
6-9 MONTHS 
  Tacrolimus  Cyclosporine  P 
Tremor Present 6 9 0.412 
Absent 23 21 
Paresthesia Present 0 0 0 
Absent 29 30 
Hypertension Present 3 5 0.478 
Absent 26 25 
NODAT Present 3 1 0.284 
Absent 26 29 
Clinical toxicity 
Present  7 8 
0.824 
Absent 22 22 
Graft 
dysfunction 
Present  7 15 
0.404 
Absent  22 15 
Toxicity on 
HPE 
Present  0 2 
0.157 
Absent  29 28 
 
There was no significant correlation between tacrolimus and 
cyclosporine in manifestation of tremor, paresthesia, hypertension, 
NODAT, overall clinical toxicity, graft dysfunction and histopathological 
toxicity 
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TACROLIMUS VS CYCLOSPORINE 
>9 MONTHS 
  Tacrolimus  Cyclosporine  P 
Tremor Present 6 3 0.061 
Absent 11 23 
Paresthesia Present 0            0 0 
Absent 17 26 
Hypertension Present 2 1 0.319 
Absent 15 25 
NODAT Present 1 0 0.211 
Absent 16 26 
Clinical toxicity 
Present  7 3 
     0.204 
Absent 10 23 
Graft 
dysfunction 
Present  0 3 
      0.146 
Absent  17 23 
 
             There was no significant correlation between tacrolimus and 
cyclosporine in manifestation of tremor, paresthesia, hypertension, 
NODAT, overall clinical toxicity and graft dysfunction. 
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DISCUSSION 
In  our  study  total  of  sixty  one  renal  allograft  recipients  who  
underwent renal allograft transplantation from June 2012 to June 2013 at 
our centre were included.   Followed up for the period of 0-18 month 
(median of 12.5 months) for calcineurin inhibitor toxicity. Out of sixty 
one 83.6% (51) were male and 16.4 %( 10) were female, majority of 
them were in third decade of life. Among donors, live versus deceased 
donor was 70.5% (43) and 29.5% (18). Majority of the live donors were 
mother 44.2 %( 19) followed by spouse 30.2% (13). 
Prevalence of clinical calcineurin inhibitor toxicity was 60.7%(37), 
39.3%(24), 25.4%(15)  and 23.3%(10) at 0-3, 3-6, 6-9, and >9 months 
respect tively. Among  clinical features tremor and hypertension were  
present in majority of the recipients [tremor: 39.3%(24), 34.4% (21) , 
25.4% (15)  and 20.9% (9); hypertension: 39.3% (24), 31.1% (19) , 
13.6% (6)  and 7% (3)  at 0-3, 3-6, 6-9  and >9 months respectively]. 
NODAT was present in 4.9% (93) in 0-3 & 3-6 months, 6.8% (4) in 6-9 
months and 2.3% (1) in more than 9 months.  Graft dysfunction was in 
37.7% (23), 23% (14) , 37.3% (22), and 7% (3)  at 0-3, 3-6, 6-9 month 
and thereafter. Elevated  trough level was seen in 29.5% (18) , 27.9% 
(17), 32.2% (19) and 18.6% (8) at  0-3, 3-6, 6-9 month and thereafter. 
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Neeraja kambham20 et al shown that incidence of hypertension was 
24% at 3 and 6 months and 18% at 12 months. 
Jose  M  morale21 et al shown that prevalence of hypertension was 
60-85% in patients on calcineurin inhibitors. More than fifty percent of 
well functioning graft showed arterial hypertension. 
Vincenti22 et al shown that prevalence of  new onset diabetes after 
trans plantation was 15%.   
Zibiti23 et  al  shown that  after  a  mean transplantation time of three 
months, 14/92 (15.2%) transplanted patients developed NODAT in his 
study of 92patients. 
Sitagourishankar24et al shown that prevalence of new onset 
diabetes was 6.7% at 6 months, 7.0% at 12 months and 8.0% at 3 years 
post transplant (study on 386 adult kidney transplant recipient). Incidence 
of new onset diabetes in our study coincides with him. 
In our  study trough level  was significantly correlated with tremor 
and clinical toxicity at 3-6 and 6-9 month(P<0.001). Trough level doesn’t 
correlate with  tremor, hypertension, NODAT, graft dysfunction. In 0-3 
and more than nine months trough level didn’t correlate with clinical 
toxicity, graft dysfunction and histopathological toxicity. 
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Maryam hami et al shown that in his study among 50 kidney 
transplant recipients from one week to six months of post transplant age 
shown that  no significant relationships neither between serum 
cyclosporine levels and graft function nor between cyclosporine dose and 
CO, except at second week and sixth month after transplantation. After 
fourth month, none the patients with low Co levels had tremor, but 24.7% 
of the patients with Co levels within therapeutic level and 66.7% with Co 
levels higher than the therapeutic level had tremor, no significant relation 
between Co level and blood glucose and blood pressure.  
In our  study 6, 5 and 2 patients at 0-3months, 3-6 months and 6-9 
months  showed evidence of calcineurin inhibitor toxicity  in renal 
biopsy. Isometric vacuolization was seen in all thirteen biopsies, 
medullary hyalinosis was seen in three of thirteen biopsies and 
thrombotic microangiopathy in one biopsy.  
Alok Sharma25 et al from AIIMS shown that in his 140 protocol 
biopsy study among kidney transplant recipients, histopathological 
evidence of toxicity was present in 10.3%, 13.3%, and 5.4%  at one 
month, sixth month and twelve month. Among histological features 
arterial hyalinosis was significantly correlated feature of CNI toxicity. 
Higher number of isometric vacuolization in our study might be 
due to acute CNI toxicity. 
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Neeraja kampham et al shown that the incidence of CNI toxicity 
was higher in protocol biopsy over clinically indicated biopsies 41.5% vs 
22%. 
In our study analysis of trough level vs hypertension, tremor, new 
onset diabetes, overall clinical toxicity, graft dysfunction and 
histopathological toxicity were not correlated significantly at 0-3, 3-6, 6-
9 and more than 9 months except trough level versus  tremor and overall 
clinical toxicity  at 3-6 and 6-9 months. 
In our study there was no significant correlation  between clinical 
toxicity, trough level, graft dysfunction and histopathological correlation 
at 0-3, 3-6, 6-9 and >9 months. 
Karel karejci26 et  al  also  shown  that  there  was  no  significant  
correlation  between graft dysfunction, elevated trough level and 
histopathological   toxic features  at 3 weeks, 3months and 1 year. 
In our study tacrolimus and cyclosporine was compared. Statistical 
analysis shown that there was significant correlation between tremor and 
elevated trough level at 0-3 and 3-6 months. There was no significant 
correlation between trough level and hypertension, new onset diabetes, 
graft dysfunction and histopathological toxicity. 
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Martins27 et  al  showed  that  in  his  study  of  tacrolimus  vs  
cyclosporine in renal allograft recipient, tacrolimus patients showed 
better renal function; namely, creatinine was 1.15 +/- 0.27 versus 1.44 +/- 
0.33 mg/dL (P =.029). Lipid and blood pressure values were not different 
between the 2 subgroups, the incidence of de novo diabetes mellitus was 
approximately 20% among patients using tacrolimus 
Margreiter28 et al in his comparative study of tacrolimus vs 
cyclosporine(micro emulsion)  in 560 patients shown that the overall 
frequency of adverse events was similar in the two groups, though 
hypertension and hypercholesterolemia were more common in the 
cyclosporine group and tremor and hypomagnesaemia were more 
frequent in the tacrolimus group. 
Angela C Webster29 et al in his meta analysis of tacrolimus vs 
cyclosporine from 30 trials shown that at one year, tacrolimus treated 
patients had less acute rejection (RR = 0.69, 0.60 to 0.79) and less steroid 
resistant rejection (RR = 0.49, 0.37 to 0.64) but more diabetes mellitus 
requiring insulin (RR = 1.86, 1.11 to 3.09), tremor, headache. The 
relative excess of diabetes was increased with higher concentrations of 
tacrolimus (P = 0.003). 
 
 
Conclusion 
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CONCLUSION 
1. In our study a significant correlation between tremor, clinical 
toxicity and elevated trough (Co) level at 3-6 and 6-9 month (P<0.001) 
was observed. 
3. There was no significant correlation between clinical toxicity, 
trough level, graft dysfunction and histopathological correlation at 0-3, 3-
6, 6-9 and >9 months. 
4. There was a significant correlation between tremor and elevated 
trough level of tacrolimus was observed at 0-3 and 3-6 months. 
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1 P 26 M IGA CGN 6/18/2012 18 FATHER 51 M LD N 0.8 3 CSA 250 295 YES 250>225 Y N N N N YES 0.8 N 134 3.7 156 N N N N
2 K 22 M HORSE SHOE 6/19/2012 18 mother 45 F LD N 2.1 1 CSA 225 215 NO N N N N N NO 1.1 N 142 4.2 156 N N N N
3 L 42 M CGN 6/21/2012 18 SPOUSE 41 F LD N 1.7 1 TAC 5 6 NO 5>4.5 Y N N Y N YES 1.8 N 138 3.8 145 N N N N
4 R 47 M DKD 6/22/2012 18 25 M DD N 1 1 TAC 6 4.1 NO N N N N N NO 1.1 N 130 4.2 206 N N N N
5 C 47 M CGN 6/26/2012 18 SPOUSE 36 F LD N 0.9 1 TAC 5 5.8 NO N N N N N NO 1 N 135 4.2 156 N N N N
6 R 27 M CGN HCV 7/7/2012 17 25 M DD N 1.3 1 CSA 250 260 YES 250>225 N N N N N NO 1.5 Y 140 4.4 165 N N N N
7 M 44 M CGN 7/9/2012 17 WIFE 39 F LD N 1 1 TAC 6 5.5 NO 6>5 N N N Y N YES 1.7 Y 142 4.6 167 N N N N
8 M 40 M CGN 7/10/2012 17 MOTHER 56 F LD N 1.2 3 CSA 250 220 YES N N N N N NO 1.1 N 136 3.9 210 N N N N
11 M 32 M NK 7/16/2012 17 14 M DD N 1.4 2 TAC 7 8.6 YES 7>6 Y N N Y N YES 1.4 N 145 4.5 180 N N N N
12 M 45 M CGN 7/17/2012 17 WIFE 35 F LD Y 1.2 1 TAC 6 28 YES 4>3>1.5 N Y N Y N YES 1.4 Y 138 4.2 185 Y N N N
13 B 22 F NK 7/19/2012 17 mother 45 LD N 1 1 CSA 275 234 NO 275>250 Y N N Y N YES 1.4 Y 140 4.2 160 N N N N
14 S 46 M NK 7/28/2012 17 42 M DD Y 2 1 TAC 5 14.7 YES 5>4 N N N Y N YES 2.9 Y 135 4.5 145 N Y Y N
15 M 17 M CGN 8/14/2012 16 MOTHER 36 F LD N 1 1 CSA 225 215 NO N N N N N NO 1.1 N 142 4.2 156 N N N N
17 M 43 M CGN 8/23/2012 16 SISTER 50 F LD N 1.2 1 CSA 275 245 NO N N N N N NO 1 N 132 3.7 186 N N N N
18 D 26 M CGN 8/28/2012 16 FATHER 55 M LD N 1.3 2 CSA 375 240 YES 375>350 y N N N N YES 1.3 N 136 4.6 196 N N N N
19 S 22 M CGNANCA NEG 8/31/2012 16 MOTHER 45 F LD N 1.2 1 CSA 300 204 NO N N N N N NO 0.6 N 145 4.1 158 N N N N
20 R 35 M CGN 9/11/2012 15 SPOUSE 33 F LD Y 1.2 1 TAC 6 5.5 NO 6>5 N N N Y N YES 1.7 Y 142 4.6 167 N N N N
21 E 28 M NK 9/20/2012 15 MOTHER 55 F LD N 2.1 1 CSA 275 197 NO 275>250 Y N N Y N YES 2.8 Y 140 3.9 168 N N N N
22 K 49 F NK 9/21/2012 15 28 M DD Y 1.2 1 TAC 5 6 NO N N N N N NO 1.1 N 136 3.8 156 N N N N
23 S 17 M CGN 9/24/2012 15 FATHER 55 M LD N 0.8 3 CSA 225 236 YES 225>200 Y N N N N YES 1.8 Y 140 3.9 168 N N N N
24 V 34 M CIN 9/25/2012 15 SPOUSE 28 F LD Y 1.3 3 TAC 6 8.6 YES 6>5 Y N N N N YES 1.4 N 138 3.8 170 N N N N
25 S 40 M NK 9/30/2012 15 40 M DD N 0.9 1 TAC 3.5 4.7 NO N N N N N NO 0.9 N 145 3.7 189 N N N N
27 N 20 F CGN 10/9/2012 14 mother 50 F LD N 1 1 CSA 275 234 NO 275>250 Y N N Y N YES 1.4 Y 140 4.2 160 N N N N
28 D 56 M NK 10/12/2012 14 35 M DD Y 1.2 2 TAC 5 4.5 NO N N N N N NO 1 N 142 3.8 187 N N N N
29 S 22 M IGA CGN 10/16/2012 14 20 M DD Y 1.4 3 TAC 6 23.3 YES 4 Y N N N N YES 0.8 N 140 3.7 168 N N N N
30 V 27 M CGN 10/18/2012 14 MOTHER 55 F LD N 1.9 1 CSA 300 235 NO 300>275 Y N N Y N YES 2.2 Y 140 3.5 145 N N N N
32 S 40 M CGN 10/30/2012 14 mother 55 F LD N 1 3 CSA 275 196 NO Y N N N N YES 1.4 Y 146 3.8 138 N N N N
33 J 21 F CGN 11/9/2012 13 MOTHER 40 F LD N 1.7 1 CSA 225 215 NO N N N N N NO 1.1 N 142 4.2 156 N N N N
34 E 27 M MN CGN 11/15/2012 13 SISTER 45 F LD N 0.9 1 CSA 275 234 NO 275>250 Y N N Y N YES 1.4 Y 140 4.2 160 N N N N
35 M 50 M CGN 11/20/2012 13 SISTER 55 F LD N 1.2 1 CSA 250 240 NO N N N N N NO 1 N 145 3.9 190 N N N N
37 M 43 M CGN 11/27/2012 13 43 M DD Y 1 1 TAC 6 5.5 NO 6>5 N N N Y N YES 1.7 Y 142 4.6 167 N N N N
38 M 36 M NK 11/27/2012 13 MOTHER 55 F LD N 1.3 1 CSA 350 143 NO 350>325 Y N N Y N YES 1.7 Y 138 3.8 160 N Y N N
40 R 30 M NK 12/11/2012 12 MOTHER 55 F LD N 1.2 1 CSA 225 240 NO N N N N N NO 1 N 138 3.8 190 N N N N
41 K 34 F CGN 12/18/2012 12 mother 54 F LD N 1.1 1 CSA 300 281 YES 300>275 Y N N N N YES 1 N 136 4.2 210 N N N N
42 K 45 F NK 12/20/2012 12 50 M DD Y 1.5 1 TAC 6 5.5 NO 6>5 N N N Y N YES 1.7 Y 142 4.6 167 N N N N
44 P 18 M NK 12/24/2012 12 FATHER 54 M LD N 1 2 CSA 275 330 YES 275>225 N N N N N NO 2.4 Y 145 4.5 167 N N N N
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45 E 29 M NK 1/22/2013 11 SPOUSE 26 F LD Y 1.1 1 TAC 7 5.6 NO N N N N N NO 1.2 N 138 3.8 167 N N N N
46 P 25 F CGN 1/27/2013 11 14 M DD Y 1 1 TAC 6 5.5 NO 6>5 N N N Y N YES 1.7 Y 142 4.6 167 N N N N
47 M 24 M CGN 1/28/2013 11 MOTHER 46 F LD N 1.2 3 CSA 350 202 YES 350>250 Y N N N N YES 1.4 Y 145 3.9 156 N N N N
48 M 20 F CGN 1/31/2013 11 FATHER 55 M LD N 1.1 2 CSA 225 242 YES N N N N N NO 1 N 138 3.6 178 N N N N
49 S 33 M NK 2/7/2013 10 mother 52 F LD N 1.8 1 CSA 350 278 YES 350>300 Y N N Y N YES 2.3 Y 143 3.2 216 N N N N
50 V 26 M NK 2/18/2013 10 MOTHER 40 F LD N 1.6 1 CSA 325 91 NO 325>300 Y N N Y N YES 1.7 N 138 3,8 196 N Y Y N
51 P 36 M CGN 2/28/2013 10 MOTHER 50 F LD N 1 1 CSA 300 178 NO 300>275 Y N N Y N YES 1.2 N 143 3.7 210 N Y N N
52 B 31 M HBV CGN 3/12/2013 9 SPOUSE 25 F LD Y 1 2 TAC 5 3.4 NO 5>4.5 Y N N Y N YES 1.1 N 142 4.6 189 N N N N
53 S 31 M NK 3/17/2013 9 45 M DD Y 1.6 1 TAC 6 5.5 NO 6>5 N N N Y N YES 1.7 N 142 4.6 167 N N N N
54 E 42 M NK 3/17/2013 9 42 M DD Y 1.9 1 TAC 5 6 NO N N N N N NO 1.1 N 136 3.8 156 N N N N
55 R 32 M NK 3/20/2013 9 30 M DD Y 0.9 1 TAC 3.5 4.7 NO N N N N N NO 0.9 N 145 3.7 189 N N N N
56 J 28 M CGN 3/25/2013 9 MOTHER 55 F LD N 1.6 1 CSA 350 290 YES 350>325 N N N Y N YES 1.6 N 130 3.8 187 N N N N
57 E 36 M CIN 3/26/2013 9 SISTER 42 F LD N 1 3 CSA 300 137 NO 300>250 Y N N N N YES 1.5 Y 138 3.9 196 N N N N
58 M 22 M CGN 3/28/2013 9 FATHER 50 M LD N 1.8 1 CSA 350 209 NO 350>300 N N N N N NO 2.2 Y 143 3.6 210 N Y N N
59 A 24 M HBV CGN 4/2/2013 8 53 M DD Y 1 3 TAC 4 2 NO N N N N N NO 1.2 N 140 3.9 156 N N N N
60 M 34 M CGN 4/4/2013 8 SPOUSE 24 F LD N 1 1 TAC 6 2 NO 6>5>4>3 Y N N N N YES 1.4 Y 130 3.8 187 N Y N N
61 H 24 F NK 4/9/2013 8 24 F DD Y 1.3 1 TAC 6 5.5 NO 6>5 N N N Y N YES 1.7 Y 142 4.6 167 N N N N
62 A 50 M CIN 4/16/2013 8 SPOUSE 40 F LD Y 1 3 TAC 4 5.8 NO N N N N N NO 1 N 147 4.7 190 N N N N
63 N 35 F NK 4/25/2013 8 38 M DD Y 3.2 1 TAC 6 5.5 NO 6>5 N N N Y N YES 1.7 N 142 4.6 167 N N N N
64 P 55 M CIN 4/26/2013 8 SPOUSE 50 F LD Y 1 3 TAC 7 7.5 YES 7>6.5 Y N N N N YES 1.2 N 142 4.2 187 Y N N N
65 P 28 M CGN 4/30/2013 8 FATHER 52 M LD N 1.2 2 CSA 225 210 YES 225>175 Y N N Y N YES 1.4 N 146 3.5 167 N N N N
67 S 30 M NK 5/14/2013 7 SPOUSE 23 F LD Y 1 3 TAC 4 4 NO N N N N N NO 1.1 N 137 3.7 180 Y N N N
70 R 28 M NK 5/28/2013 7 SPOUSE 25 F LD Y 1.1 3 TAC 4 5.2 NO 4>3 Y N N N N YES 1.2 N 140 4.1 196 N N N N
71 E 43 M NK 6/5/2013 6 23 M DD Y 0.9 2 TAC 4 4.5 NO N N N N N NO 1 N 135 3.2 187 N N N N
74 S 27 M CGN 6/18/2013 6 MOTHER 51 F LD N 1.4 1 CSA 250 155 NO N Y N N N YES 1.5 N 146 3.9 167 N N N N
